IL-4 and IL-13 receptors: Roles in immunity and powerful vaccine adjuvants

Charani Ranasinghe; Shubhanshi Trivedi; Danushka K Wijesundara; Ronald J Jackson

doi:10.1016/j.cytogfr.2014.07.010

IL-4 and IL-13 receptors: Roles in immunity and powerful vaccine adjuvants

Cytokine Growth Factor Rev. 2014 Aug;25(4):437-42. doi: 10.1016/j.cytogfr.2014.07.010. Epub 2014 Jul 23.

Authors

Charani Ranasinghe¹, Shubhanshi Trivedi², Danushka K Wijesundara³, Ronald J Jackson²

Affiliations

¹ Molecular Mucosal Vaccine Immunology Group, Department of Immunology, The John Curtin School of Medical Research, The Australian National University, Canberra ACT 0200, Australia. Electronic address: Charani.Ranasinghe@anu.edu.au.
² Molecular Mucosal Vaccine Immunology Group, Department of Immunology, The John Curtin School of Medical Research, The Australian National University, Canberra ACT 0200, Australia.
³ Molecular Mucosal Vaccine Immunology Group, Department of Immunology, The John Curtin School of Medical Research, The Australian National University, Canberra ACT 0200, Australia; Virology Laboratory, The Basil Hetzel Institute, Department of Surgery, The University of Adelaide, Adelaide, South Australia, Australia.

PMID: 25159217
DOI: 10.1016/j.cytogfr.2014.07.010

Abstract

The roles of interleukin (IL)-4 and IL-13 during both innate and adaptive Th2 mediated immunity have received considerable scrutiny, however, mechanisms by which these cytokines influence the cellular interactions involved in negatively modulating the development of effective Th1 immunity are poorly characterized. In this article we discuss the recent advances in IL-4/IL-13 biology, mainly (i) role of these cytokines in allergic inflammation, atopic dermatitis, cancer, transplant rejection, bacterial/viral infections, and specifically the therapeutic potential of IL-13Rα2, (ii) insights into how "alarmin" stimulation activate IL-4/IL-13 at the lung mucosae, (iii) how these two cytokines modulate antigen-specific CD8(+) T cell quality/avidity in a vaccine route dependent manner and (iv) finally discuss the potential of using transient inhibition of IL-4 and/or IL-13 at the vaccination site as a platform vaccine technology to induce strong sustained high quality CD8(+) T cell immunity for protection against many chronic mucosal pathogens such as HIV-1.

Keywords: CD8 T cell avidity; IL-13Ra2; IL-4R antagonist; Infection and immunity; Vaccines.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

AIDS Vaccines / immunology
Acquired Immunodeficiency Syndrome / immunology
Acquired Immunodeficiency Syndrome / prevention & control
Adjuvants, Immunologic / therapeutic use
CD8-Positive T-Lymphocytes / immunology*
Humans
Hypersensitivity / immunology
Interleukin-13 / antagonists & inhibitors
Interleukin-13 / immunology*
Interleukin-13 Receptor alpha2 Subunit / immunology*
Interleukin-4 / antagonists & inhibitors
Interleukin-4 / immunology*
Neoplasms / immunology
Receptors, Interleukin-4 / immunology*
Th1 Cells / immunology
Th2 Cells / immunology

Substances

AIDS Vaccines
Adjuvants, Immunologic
IL4 protein, human
Interleukin-13
Interleukin-13 Receptor alpha2 Subunit
Receptors, Interleukin-4
Interleukin-4